In 2019, Putnam formed a select panel of cell and gene therapy (CGT) experts to meet our clients’ growing demand for CGT strategy and commercialization support. By engaging with our expert panel, Putnam is at the leading edge of this rapidly evolving space, delivering to our CGT-focused clients unparalleled insight into clinical decision-making, product on-boarding and logistical challenges, emerging technologies, and key market trends.
In the lead-up to ASH, Putnam held our first CGT roundtable event with four leading experts from our panel. Joseph Feingold and Colleen Sadin, leaders of Putnam’s CGT practice, moderated the discussion on the current and future state of CAR-T cell therapy in oncology: “Three years of commercial CAR-T: Where are We and Where are we headed?”
Below are a few highlights from our discussion. We will be sharing more in the coming weeks. Stay tuned!